Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | BRD4 | O60885 | 12/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11636791 | 0.93 | GABRA1 (0.76) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL23109728 | 0.91 | LMNA (0.60) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL7318994 | 0.89 | GABRA1 (0.71) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL16771529 | 0.86 | GABRA1 (0.61) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL14756888 | 0.84 | GABRA1 (0.71) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL9378858 | 0.84 | GABRA1 (0.71) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| SCHEMBL14757175 | 0.84 | BRD4 (0.59) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| Alprazolam SCHEMBL16922178 | 0.81 | GABRA1 (1.00) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| Alprazolam SCHEMBL8398 | 0.81 | GABRA1 (1.00) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 | |
| Alprazolam SCHEMBL5480614 | 0.81 | GABRA1 (1.00) | LMNASMN1; SMN2ALDH1A1BRD4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192642-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021183431-A1 | FEM1B PROTEIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3129378-B1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3050885-B1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017157813-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| US-20170145021-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2017-05-25 | — | — | US | disclosed |
| US-20150210706-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2015-07-30 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | LMNA 3085/4885SMN1; SMN2 1838/4885ALDH1A1 3671/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | LMNA 1674/4885SMN1; SMN2 1805/4885ALDH1A1 2592/4885 |
| US-20170145021-A1 | NOVEL COMPOUNDS | GABRE, GABRA1, GABRA6 | LMNA 2687/4885SMN1; SMN2 1660/4885ALDH1A1 996/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | LMNA 3085/4885SMN1; SMN2 1838/4885ALDH1A1 3671/4885 |
| US-20150210706-A1 | Benzodiazepine Bromodomain Inhibitor | BRD4, BRD3, BRD2 | LMNA 2021/4885SMN1; SMN2 3578/4885ALDH1A1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.